MedTrace Logo

Tabata Exercise on Nitric Oxide Synthases and Maresin

NCT07412639 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-17

No results posted yet for this study

Summary

Smoking causes chronic inflammation and endothelial dysfunction through alterations in nitric oxide synthase (NOS) pathways. Maresin is an anti-inflammatory pro-resolving lipid mediator that plays important roles in the resolution of inflammatory processes. Tabata exercise is a short-duration, high-intensity exercise modality with beneficial effects on the cardiovascular system. The aim of this study was to comparatively evaluate the effects of tabata exercise on iNOS, eNOS, and Maresin levels, as well as the relationships among these biomarkers, in smokers and non-smokers.

Conditions

  • Smoking
  • Smoking, Cigarette

Interventions

OTHER

Tabata Exercise Protocol

The Tabata protocol consisted of 20-second high-intensity intervals exceeding 70 % of VO₂max and approaching \~90 % of VO₂max, followed by 10 seconds of rest, repeated for 4 minutes per set. Exercises included high knees, froggers, speed skaters, jumping jacks, and mountain climbers. Following the original Tabata design \[29\], each work-rest cycle was repeated eight times. Each training session began with a 10-15 minute warm-up and concluded with a 10-15 minute cool-down. The total number of sets ranged from 1 to 4, and the number of exercises per session ranged from 4 to 8. Training intensity progressively increased from 30 % to 89 % of maximal effort according to the principle of progressive overload.

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-24
Primary Completion
2026-01-16
Completion
2026-01-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07412639 on ClinicalTrials.gov